Skip to content
Bored Studies
RecruitingPhase 3

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)

Merck Sharp & Dohme LLC · NCT07705607

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
1104
US sites recruiting
19
Study start
September 25, 2026
Record last updated
October 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME. An available standard (usual) treatment for DME is aflibercept. However, standard treatments such as aflibercept may not work for every person.

The main goal of this trial is to learn if MK-8748 works as well as aflibercept to treat DME.

Being studied: MK-8748; Aflibercept

Conditions: Diabetic Retinopathy; Macular Edema

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

The main inclusion criteria include but are not limited to the following:

  • Has Type 1 or Type 2 diabetes mellitus and a hemoglobin A1c (HbA1c) of ≤12%
  • Has a decrease in vision in the study eye determined by the Investigator to be primarily the result of diabetic macular edema (DME)
  • For participants who are treatment-naïve for DME, the diagnosis must have been made within 9 months of screening. For all treatment-experienced participants, the first treatment should have been no longer than 3 years prior to the Screening visit

Exclusion Criteria

The main exclusion criteria include but are not limited to the following:

  • Has had renal failure requiring renal transplant, hemodialysis, or peritoneal dialysis or has renal failure anticipated to require hemodialysis or peritoneal dialysis at any time during the study
  • Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days to first dose of study intervention
  • Has newly diagnosed or previously untreated diabetes mellitus and initiated oral or injectable anti-diabetic medication within 3 months to first dose of study intervention
  • Has history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening
  • Has any treatment for complications of cataract surgery with steroids or yttrium aluminum garnet (YAG) laser capsulotomy in the study eye within 90 days of screening
  • Has advanced or uncontrolled glaucoma in the study eye
  • Has any history of retinal detachment or treatment or surgery for retinal detachment in the study eye
  • Has active retinal disease other than the condition under investigation in the study eye
  • Has uncontrolled blood pressure at screening

Recruiting US locations

  • Retina Group of New England ( Site 0101)

    Waterford, CT 06385

    Site contact: Study Coordinator · 860-444-1292

  • Florida Retina Institute ( Site 0035)

    Orlando, FL 32806

    Site contact: Study Coordinator · 407-849-9621

  • Retina Vitreous Associates of Florida ( Site 0036)

    St. Petersburg, FL 33711

    Site contact: Study Coordinator · 727-323-0077

  • Center for Retina and Macular Disease ( Site 0047)

    Winter Haven, FL 33880

    Site contact: Study Coordinator · 863-297-5400

  • Associated Vitreoretinal and Uveitis Consultants ( Site 0099)

    Carmel, IN 46032

    Site contact: Study Coordinator · 317-571-1501

  • Wolfe Eye Clinic ( Site 0044)

    West Des Moines, IA 50266

    Site contact: Study Coordinator · 515-223-8685

  • Cumberland Valley Retina Consultants ( Site 0003)

    Hagerstown, MD 21740

    Site contact: Study Coordinator · 301-665-1712

  • Retina-Vitreous Surgeons of Central NY ( Site 0021)

    Liverpool, NY 13088

    Site contact: Study Coordinator · 315-445-8166

  • North Carolina Retina Associates ( Site 0122)

    Greenville, NC 27834

    Site contact: Study Coordinator · 919-782-8091

  • Graystone Eye ( Site 0059)

    Hickory, NC 28602

    Site contact: Study Coordinator · 828-304-6643

  • Piedmont Retina Specialists ( Site 0049)

    Winston-Salem, NC 27103

    Site contact: Study Coordinator · 336-397-9216

  • Palmetto Retina Center ( Site 0073)

    Aiken, SC 29801

    Site contact: Study Coordinator · 803-931-0077

  • Charleston Neuroscience Institute ( Site 0090)

    Beaufort, SC 29902

    Site contact: Study Coordinator · 843-763-4466

  • Charleston Neuroscience Institute ( Site 0076)

    Charleston, SC 29414

    Site contact: Study Coordinator · 843-763-4466

  • Retina Consultants of South Carolina ( Site 0026)

    Ladson, SC 29456

    Site contact: Study Coordinator · 843-763-4466

  • Texas Retina ( Site 0051)

    Arlington, TX 76012

    Site contact: Study Coordinator · 817-261-9625

  • Texas Retina Associates ( Site 0055)

    Fort Worth, TX 76104

    Site contact: Study Coordinator · 817-334-0882

  • Retina Consultants of Texas - Katy/Cinco Ranch ( Site 0100)

    Katy, TX 77494

    Site contact: Study Coordinator · 713-524-3434

  • Retina Center of Texas ( Site 0096)

    Southlake, TX 76092

    Site contact: Study Coordinator · 817-865-6800

Study contacts (from the official record)

  • Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
All diabetes studies in Connecticut →
A Clinical Trial of MK-8748 Compared to Aflibercept in… (NCT07705607) | Bored Studies